Roivant Sciences Ltd.
ROIV
$11.92
$0.110.93%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -35.86% | -11.19% | -40.27% | -29.51% | -41.05% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -35.86% | -11.19% | -40.27% | -29.51% | -41.05% |
| Cost of Revenue | 31.59% | 26.39% | 55.51% | 31.59% | 17.32% |
| Gross Profit | -37.64% | -29.48% | -57.61% | -30.40% | -18.42% |
| SG&A Expenses | 58.39% | 49.85% | 57.47% | 18.02% | -8.38% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 44.05% | 37.38% | 9.29% | -9.00% | -21.97% |
| Operating Income | -47.73% | -39.42% | -12.39% | 7.82% | 20.79% |
| Income Before Tax | -119.43% | -114.92% | -112.41% | 654.62% | 610.10% |
| Income Tax Expenses | 28.53% | 124.03% | -125.37% | 430.57% | 377.41% |
| Earnings from Continuing Operations | -120.42% | -116.05% | -112.33% | 645.04% | 603.15% |
| Earnings from Discontinued Operations | 297.95% | 218.37% | 225.43% | 40.84% | -73.61% |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 65.28% | 56.94% | 97.17% | 48.84% | 28.16% |
| Net Income | -110.36% | -103.95% | -102.61% | 589.95% | 588.74% |
| EBIT | -47.73% | -39.42% | -12.39% | 7.82% | 20.79% |
| EBITDA | -50.64% | -42.68% | -12.71% | 7.77% | 21.46% |
| EPS Basic | -111.82% | -104.46% | -102.48% | 554.70% | 541.28% |
| Normalized Basic EPS | -62.50% | -12.76% | 10.31% | 40.57% | 44.03% |
| EPS Diluted | -112.63% | -104.84% | -102.68% | 527.71% | 514.76% |
| Normalized Diluted EPS | -66.64% | -13.08% | 10.24% | 42.23% | 45.42% |
| Average Basic Shares Outstanding | -8.48% | -7.40% | -1.51% | 4.03% | 7.77% |
| Average Diluted Shares Outstanding | -11.05% | -7.23% | -1.43% | 7.06% | 10.88% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |